Intellia Hires 43 New Employees Post-Phase 3 Win, Issues Inducement Grants for Commercial Build-Out

Intellia Therapeutics reports inducement grants of restricted stock units and stock options to 43 newly hired employees under Nasdaq Listing Rule 5635(c)(4), covering a broad mix of roles across scientific, clinical, and commercial functions. The hiring surge follows the landmark April 27 HAELO Phase 3 results for lonvoguran ziclumeran (lonvo-z) and reflects Intellia's acceleration of pre-commercial and regulatory activities ahead of a planned FDA BLA filing for lonvo-z in hereditary angioedema. The company raised approximately $180 million in a concurrent stock offering (priced April 29 at $10.75/share) to fund these activities. The inducement grants are structured outside Intellia's existing equity incentive plan, as permitted for new hires. This level of hiring activity signals the company's transition from a clinical-stage to a near-commercial biotech and is consistent with Intellia's stated intention to build a dedicated commercial infrastructure for what would be the first ever in vivo CRISPR gene editing drug to reach the US market.